EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors

Maria Elisa Mancuso iD, Anthony K C Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu iD, Lize F D van Vulpen, Pratima Chowdary, Renchi Yang, Steven R Lentz, Tadashi Matsushita iD, Wan Hui Ong Clausen und 3 weitere

New England Journal of Medicine · 30.04.2026 · 394 (17) · 1696-1709

DOI: 10.1056/nejmoa2517384 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 30.04.2026. Verfasst von Maria Elisa Mancuso und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Factor VIII, Hemophilia A, Hemorrhage. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mim8 (denecimig), a bispecific antibody mimicking activated factor VIII, was developed for bleeding prophylaxis in patients with hemophilia A with or without factor VIII inhibitors. METHODS: In this phase 3, randomized trial, we assigned patients 12 years of age or older with hemophilia A with or without inhibitors to receive subcutaneous Mim8 once weekly or once monthly at a dose tiered according to body weight and given in a fixed injection volume (0.8 ml). Patients who had been receiving on-demand treatment before the trial were assigned in a 1:1:1 ratio to continue on-demand treatment (group 1) or receive Mim8 once weekly (group 2a) or once monthly (group 2b). Patients who had been receiving clotting factor concentrates during a run-in phase were assigned in a 1:1 ratio to receive Mim8 once weekly (group 3) or once monthly (group 4). The first primary end point was the annualized rate of treated bleeding events (those treated with a coagulation factor product) in an evaluation of Mim8 in group 2a and Mim8 in group 2b as compared with on-demand treatment in group 1. The second was the annualized rate of treated bleeding events in an intrapatient evaluation of Mim8 in group 3 and Mim8 in group 4 as compared with clotting factor concentrate prophylaxis during the run-in phase. RESULTS: Of the 58 patients in the pretrial on-demand treatment cohort, 17 were assigned to group 1, 21 to group 2a, and 20 to group 2b. The estimated mean annualized rate of treated bleeding events was 0.57 (95% confidence interval [CI], 0.25 to 1.30) in group 2a and 0.20 (95% CI, 0.06 to 0.71) in group 2b, as compared with 15.76 (95% CI, 10.70 to 23.20) in group 1 (relative decrease, 96.4% and 98.7%, respectively; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificFactor VIIIHemophilia AHemorrhageFactor VIIIaAdolescentAdultChildFemaleHumansMaleMiddle AgedYoung AdultDrug Administration ScheduleInjections, SubcutaneousBlood Coagulation FactorsIsoantibodiesAgedTreatment Outcome

Substanzen

Antibodies, BispecificFactor VIIIprothrombin complex concentratesBlood Coagulation FactorsFactor VIIIaIsoantibodies

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan.
  • Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan.
  • McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
  • Department of Clinical Hematology, Seth G.S. Medical College and King Edward Memorial Hospital, Mumbai, India.
  • Department of Pediatrics, Yonsei University Severance Hospital, Seoul, South Korea.
  • Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.

ORCID-Profile: Maria Elisa Mancuso, Johnny Mahlangu, Tadashi Matsushita

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Mancuso, M. E., Chan, A. K. C., Shanmukhaiah, C., Lyu, C. J., Zdziarska, J., Mahlangu, J., van Vulpen, L. F. D., Chowdary, P., Yang, R., Lentz, S. R., Matsushita, T., Clausen, W. H. O., Rakhmatullin, I., Oldenburg, J., & FRONTIER2 Investigators (2026). Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. New England Journal of Medicine, 394(17), 1696-1709. https://doi.org/10.1056/nejmoa2517384

Vancouver

Mancuso ME, Chan AKC, Shanmukhaiah C, Lyu CJ, Zdziarska J, Mahlangu J, et al. Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. New England Journal of Medicine. 2026;394(17):1696-1709. doi:10.1056/nejmoa2517384

BibTeX
@article{Mancuso2026,
  author = {Mancuso, Maria Elisa and Chan, Anthony K C and Shanmukhaiah, Chandrakala and Lyu, Chuhl Joo and Zdziarska, Joanna and Mahlangu, Johnny and van Vulpen, Lize F D and Chowdary, Pratima and Yang, Renchi and Lentz, Steven R and Matsushita, Tadashi and Clausen, Wan Hui Ong and Rakhmatullin, Ilgiz and Oldenburg, Johannes and FRONTIER2 Investigators, FRONTIER2 Investigators},
  title = {Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {17},
  pages = {1696--1709},
  doi = {10.1056/nejmoa2517384}
}
Kostenlos starten →